Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Crea, Filippo; Thiele, Holger; Sibbing, Dirk; Barthélémy, Olivier; Bauersachs, Johann; Bhatt, Deepak L; Dendale, Paul; Dorobantu, Maria; Edvardsen, Thor; Folliguet, Thierry; Gale, Chris P; Gilard, Martine; Jobs, Alexander; Jüni, Peter; Lambrinou, Ekaterini; Lewis, Basil S; Mehilli, Julinda; Meliga, Emanuele; Merkely, Béla; Mueller, Christian; Roffi, Marco; Rutten, Frans H; Siontis, George C M; Barbato, Emanuele; Collet, Jean-Philippe; Giannitsis, Evangelos; Hamm, Christian W; Böhm, Michael; Cornel, Jan H; Ferreiro, José Luis; Frey, Norbert; Huber, Kurt; Kubica, Jacek; Navarese, Eliano P; Mehran, Roxana; Morais, Joao; Storey, Robert F; Valgimigli, Marco; Vranckx, Pascal; James, Stefan

doi:10.1093/eurheartj/ehab277

Scientific article

English

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Published inEuropean heart journal, vol. 42, no. 31, p. 2973-2985

Publication date2021-08-17

Keywords

Clopidogrel
Humans
Percutaneous Coronary Intervention
Prasugrel Hydrochloride / therapeutic use
Purinergic P2Y Receptor Antagonists
Ticagrelor / therapeutic use

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Citation (ISO format)

CREA, Filippo et al. Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. In: European heart journal, 2021, vol. 42, n° 31, p. 2973–2985. doi: 10.1093/eurheartj/ehab277

Article (Published version)

Identifiers

PID : unige:163453
DOI : 10.1093/eurheartj/ehab277
PMID : 34110420

Journal ISSN0195-668X

169views

0downloads

Creation21/02/2022 15:36:00

First validation21/02/2022 15:36:00

Update16/03/2023 07:36:00

Status update16/03/2023 07:35:56

Last indexation01/11/2024 02:45:30

Archive ouverte UNIGE

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Technical informations